KRAS-IN-55 

KRAS-IN-55 is a pan-KRAS inhibitor with IC₅₀ values of 4.3, 9.6 and 1.6 nM against KRAS^G12C, KRAS^G12D and KRAS^G12V, respectively. KRAS-IN-55 induces the formation of a new binding pocket on KRAS, thereby forming a high-affinity ternary complex with cyclophilin A (CYPA), inhibiting the interactions of KRAS with downstream effectors RAF and PI3K, and blocking oncogenic MAPK and PI3K signaling pathways. KRAS-IN-55 is applicable to cancer research such as colorectal cancer and non-small cell lung cancer^[1].

KRAS-IN-55 (Example 2) (72 h) inhibits the viability of KRAS^G12C, KRAS^G12D, and KRAS^G12V mutant cancer cells, with an IC₅₀ of 15.2 nM in NCI-H358 cells, 10.5 nM in AGS cells, 2.8 nM in SW620 cells^[1].
KRAS-IN-55 (0.0001-10 μM; 3 h) inhibits the interaction between KRAS^G12C, KRAS^G12D, KRAS^G12V and BRAF_rbd, with an IC₅₀ of 0.008 μM against KRAS^G12C, 0.044 μM against KRAS^G12D, and 0.010 μM against KRAS^G12V[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

892.09

C₄₈H₅₈FN₉O₅S

CCC1=[C@](N2CC(C)(COC([C@@H]3CCCN(C([C@H](CC4=NC(C5=C(C2=C1C=C5)F)=CS4)NC([C@H]6C[C@@H]6C7=CN=CC=C7)=O)=O)N3)=O)C)[C@]8=C(N=CC(N9CCN(CC9)C)=C8)[C@@H](OC)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chen, Jianguo, et al. Preparation of macrocycle compounds for treatment of cancer as KRAS inhibitors. WO2026041636.